miRNA-based therapy

About SiSaf

SiSaf is a private, clinical-stage biotech leveraging its unique Bio-Courier® delivery platform to advance a pipeline of RNA therapeutics. Its lead program, a siRNA therapy for Osteopetrosis Type II (ADO2), has secured FDA Orphan Drug and Rare Pediatric Disease designations and is progressing toward an IND. The company's technology differentiates itself from standard LNPs by enabling room-temperature storage and separate manufacturing of the carrier and payload, potentially simplifying logistics and expanding therapeutic applications. SiSaf is funded through venture capital and strategic partnerships.

Therapeutic Areas